Abstract—Novel treatments for various types of malignant diseases are warranted. In this study, we evaluated JAK2 inhibitors (Janus kinase 2) for suppressing the growth of malignant neuroblastoma and glioblastoma cells as well as breast and non-small cell lung cancers. Neuroblastoma and glioblastoma cells are the most sensitive to the JAK2 inhibitor AG490. A study of the relative expression of receptors that can activate JAK2 suggests that cell line sensitivity to AG490 may be mediated by IL6-R, IL11-R and/or CSF1-R. AG490 enhances the effect of doxorubicin on neuroblastoma cells. Our findings suggest the possible relevance of JAK2 inhibitors for neuroblastoma therapy, especially in combination with doxorubicin.

中文翻译：

---

非受体酪氨酸激酶JAK2的抑制作用减少神经母细胞瘤细胞的生长并增强阿霉素的作用

摘要—对各种类型的恶性疾病的新颖治疗是有必要的。在这项研究中，我们评估了JAK2抑制剂（Janus激酶2）可抑制恶性神经母细胞瘤和胶质母细胞瘤细胞以及乳腺癌和非小细胞肺癌的生长。神经母细胞瘤和胶质母细胞瘤细胞对JAK2抑制剂AG490最敏感。可以激活JAK2的受体的相对表达的研究表明，细胞株对AG490的敏感性可能是由IL6-R，IL11-R和/或CSF1-R介导的。AG490增强了阿霉素对神经母细胞瘤细胞的作用。我们的发现表明，JAK2抑制剂与神经母细胞瘤治疗（尤其是与阿霉素联用）可能具有相关性。